Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) (RFA-NR-25-003)

Sponsor: National Institutes of Health

Due Date: Letter of Intent due January 29, 2025. Application due February 28, 2025.

Notice of Special Interest (NOSI): Human Cell Biology of Alzheimer's Disease Genetic Variants (NOT-AG-24-039)

Sponsor: National Institute on Aging

Award: Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice: PAR-25-331 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional); PAR-25-332 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional).

Due Date: This notice applies to due dates on or after March 11, 2025 and subsequent receipt dates through November 17, 2027.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) (PAR-25-331)

Sponsor: National Institute on Aging

Award: The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 in direct costs may be requested in any single year.

Due Date: Multiple due dates; see announcement.

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) (PAR-25-332)

Sponsor: National Institute on Aging, National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) (PAR-25-327)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) (PAR-25-326)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (RFA-EY-25-001)

Sponsor: National Institutes of Health

Award: Application budgets may not exceed $400,000 total direct costs over a maximum three-year funding period. No more than $200,000 in direct costs may be requested in any single year.

Due Date: June 17, 2025 or June 15, 2026.

Coordination Center for the Alzheimers Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed) (RFA-AG-25-015)

Sponsor: National Institute on Aging

Award: NIA intends to support 1 award. Budgets are limited to $1 million in direct costs per year. The maximum project period is 5 years.

Due Date: Letter of Intent due February 14, 2025. Application due March 14, 2025.

Deriving Common Data Elements from Real-World Data for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed) (RFA-AG-25-001)

Sponsor: National Institute on Aging

Award: NIA intends to fund 1 award. The budget for direct costs may not exceed $3,750,000 per year. The maximum project period is 5 years.

Due Date: February 28, 2025.

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) (PAR-25-224)

Sponsor: National Institute on Aging

Due Date: Application due February 21, 2025. Letter of Intent due 30 days prior to the application due date.

Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) (PAR-25-247)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (PAR-25-297)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $1,500,000 in direct costs per year and need to reflect the actual needs of the proposed project. For Early Stage projects, the project period is limited to five years. For Late Stage projects, the project period is limited to four years.

Due Date: Multiple due dates; see announcement.

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) (PAR-25-298)

Sponsor: National Institutes of Health

Award: Applicants may request up to $375,000 in direct costs for the entire project period of up to 3 years.

Due Date: Multiple due dates; see announcement.

Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) (RFA-HG-25-007)

Sponsor: National Institutes of Health

Award: Application budgets are limited to $400,000 direct costs per year. The maximum project period is 3 years.

Due Date: Letter of Intent due February 3, 2025. Application due March 03, 2025.

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (RFA-TR-25-002)

Sponsor: National Center for Advancing Translational Sciences

Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Due Date: June 02, 2025 (Letter of Intent due May 1, 2025) or June 02, 2026 (Letter of Intent due May 1, 2026).